2411: Poolbeg Pharma: What US Payers Really Said
Jun 03, 2026•15 min•Ep. 2411
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Watch on YouTube
Independent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.
For the best experience, listen in Metacast app for iOS or Android